NASDAQ:SOPH SOPHiA GENETICS (SOPH) Stock Price, News & Analysis $3.16 -0.04 (-1.25%) As of 12:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About SOPHiA GENETICS Stock (NASDAQ:SOPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SOPHiA GENETICS alerts:Sign Up Key Stats Today's Range$3.18▼$3.2350-Day Range$2.86▼$3.7552-Week Range$2.58▼$4.92Volume4,217 shsAverage Volume76,782 shsMarket Capitalization$210.73 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingBuy Company Overview SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland. Read More SOPHiA GENETICS Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreSOPH MarketRank™: SOPHiA GENETICS scored higher than 41% of companies evaluated by MarketBeat, and ranked 665th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingSOPHiA GENETICS has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageSOPHiA GENETICS has received no research coverage in the past 90 days.Read more about SOPHiA GENETICS's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for SOPHiA GENETICS are expected to grow in the coming year, from ($0.96) to ($0.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SOPHiA GENETICS is -7.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SOPHiA GENETICS is -7.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSOPHiA GENETICS has a P/B Ratio of 2.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.07% of the float of SOPHiA GENETICS has been sold short.Short Interest Ratio / Days to CoverSOPHiA GENETICS has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SOPHiA GENETICS has recently increased by 123.75%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSOPHiA GENETICS does not currently pay a dividend.Dividend GrowthSOPHiA GENETICS does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.07% of the float of SOPHiA GENETICS has been sold short.Short Interest Ratio / Days to CoverSOPHiA GENETICS has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SOPHiA GENETICS has recently increased by 123.75%, indicating that investor sentiment is decreasing significantly. News and Social Media1.9 / 5News Sentiment0.49 News SentimentSOPHiA GENETICS has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for SOPHiA GENETICS this week, compared to 2 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, SOPHiA GENETICS insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.88% of the stock of SOPHiA GENETICS is held by insiders.Percentage Held by InstitutionsOnly 31.59% of the stock of SOPHiA GENETICS is held by institutions.Read more about SOPHiA GENETICS's insider trading history. Receive SOPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SOPHiA GENETICS and its competitors with MarketBeat's FREE daily newsletter. Email Address SOPH Stock News HeadlinesSOPHiA GENETICS Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS LagsAugust 7 at 6:42 AM | finance.yahoo.comSophia Genetics SA (SOPH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...August 7 at 6:42 AM | finance.yahoo.comCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% worldwide. Now he’s applying the same expertise to the Bitcoin market. His system tracks 19 indicators to find quick Bitcoin profit opportunities.August 8 at 2:00 AM | Brownstone Research (Ad)SOPHiA GENETICS reaffirms $72M–$76M 2025 revenue guidance as AstraZeneca deal drives BioPharma outlookAugust 6 at 3:31 AM | msn.comSOPHiA GENETICS SA (SOPH) Q2 2025 Earnings Call TranscriptAugust 5 at 12:10 AM | seekingalpha.comSOPHiA GENETICS Reports Financial Results for Mid-2025August 5 at 6:59 AM | tipranks.comSOPHiA GENETICS Reports Second Quarter 2025 ResultsAugust 5 at 6:45 AM | prnewswire.comSOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomesAugust 5 at 6:40 AM | prnewswire.comSee More Headlines SOPH Stock Analysis - Frequently Asked Questions How have SOPH shares performed this year? SOPHiA GENETICS's stock was trading at $3.07 at the start of the year. Since then, SOPH stock has increased by 4.0% and is now trading at $3.1940. How were SOPHiA GENETICS's earnings last quarter? SOPHiA GENETICS SA (NASDAQ:SOPH) announced its earnings results on Tuesday, August, 5th. The company reported $0.33 earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.58. The company earned $18.32 million during the quarter, compared to analysts' expectations of $17.49 million. SOPHiA GENETICS had a negative trailing twelve-month return on equity of 30.69% and a negative net margin of 40.99%. Read the conference call transcript. When did SOPHiA GENETICS IPO? SOPHiA GENETICS (SOPH) raised $234 million in an initial public offering on Friday, July 23rd 2021. The company issued 13,000,000 shares at a price of $17.00-$19.00 per share. Who are SOPHiA GENETICS's major shareholders? SOPHiA GENETICS's top institutional shareholders include Rathbones Group PLC (0.24%), Silverberg Bernstein Capital Management LLC (0.07%), Green Alpha Advisors LLC (0.06%) and Ridgewood Investments LLC (0.05%). How do I buy shares of SOPHiA GENETICS? Shares of SOPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SOPHiA GENETICS own? Based on aggregate information from My MarketBeat watchlists, some other companies that SOPHiA GENETICS investors own include Occidental Petroleum (OXY), PayPal (PYPL), Chesapeake Energy (CHK), Cheniere Energy (LNG), Rocket Pharmaceuticals (RCKT), AbCellera Biologics (ABCL) and Farmers & Merchants Bancorp (FMAO). Company Calendar Last Earnings8/05/2025Today8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MEDICAL INFO SYS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SOPH CIK1840706 Webwww.sophiagenetics.com Phone41-21-694-1060FaxN/AEmployees520Year FoundedN/APrice Target and Rating Average Price Target for SOPHiA GENETICS$8.00 High Price Target$11.00 Low Price Target$5.00 Potential Upside/Downside+150.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($0.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$62.49 million Net Margins-40.99% Pretax Margin-102.43% Return on Equity-30.69% Return on Assets-17.39% Debt Debt-to-Equity Ratio0.62 Current Ratio3.39 Quick Ratio2.94 Sales & Book Value Annual Sales$69.69 million Price / Sales3.06 Cash FlowN/A Price / Cash FlowN/A Book Value$1.13 per share Price / Book2.83Miscellaneous Outstanding Shares66,687,000Free Float63,433,000Market Cap$213.40 million OptionableNot Optionable Beta1.00 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:SOPH) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SOPHiA GENETICS SA Please log in to your account or sign up in order to add this asset to your watchlist. Share SOPHiA GENETICS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.